FDA approves J&J's Pancreaze

FDA approved an NDA from Johnson & Johnson (NYSE:JNJ) for Pancreaze pancrelipase delayed-release capsules to treat pancreatic exocrine insufficiency. The agency said this is the third marketed pancrea...